Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Bodil Andersson
Based on 11 articles published since 2010
(Why 11 articles?)

Between 2010 and 2020, B. Andersson wrote the following 11 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Pancreatic cancer: yesterday, today and tomorrow. 2016

Ansari, Daniel / Tingstedt, Bobby / Andersson, Bodil / Holmquist, Fredrik / Sturesson, Christian / Williamsson, Caroline / Sasor, Agata / Borg, David / Bauden, Monika / Andersson, Roland. ·Department of Surgery, Clinical Sciences Lund, Lund University & Skåne University Hospital, Lund, Sweden. · Department of Radiology, Clinical Sciences Lund, Lund University & Skåne University Hospital, Lund, Sweden. · Department of Pathology, Skåne University Hospital, Lund, Sweden. · Department of Oncology, Skåne University Hospital, Lund, Sweden. ·Future Oncol · Pubmed #27246628.

ABSTRACT: Pancreatic cancer is one of our most lethal malignancies. Despite substantial improvements in the survival rates for other major cancer forms, pancreatic cancer survival rates have remained relatively unchanged since the 1960s. Pancreatic cancer is usually detected at an advanced stage and most treatment regimens are ineffective, contributing to the poor overall prognosis. Herein, we review the current understanding of pancreatic cancer, focusing on central aspects of disease management from radiology, surgery and pathology to oncology.

2 Review Single-institution experience with solid pseudopapillary neoplasm of the pancreas. 2011

Ansari, Daniel / Elebro, Jacob / Tingstedt, Bobby / Ygland, Emil / Fabricius, Madeleine / Andersson, Bodil / Andersson, Roland. ·Department of Surgery, Clinical Sciences Lund, Lund University, Sweden. ·Scand J Gastroenterol · Pubmed #22050136.

ABSTRACT: OBJECTIVE: Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare clinical entity. The objective of this study was to review a single institution's experience with this uncommon tumor, as well as review the literature. MATERIAL AND METHODS: Consecutive patients, who underwent surgery for a pathologically confirmed SPN between 1991 and 2010, were retrospectively reviewed. A PubMed search (January 1980-June 2011) was conducted to identify risk factors for death among SPN patients. RESULTS: The institutional review identified 16 patients with SPN. Thirteen patients were female and three patients were male (median age 34 years). All patients underwent radical resection. Two patients had metastatic disease at the time of operation as evident by the presence of lymph node metastasis and gallbladder metastasis. One developed liver metastasis 4 months postoperatively and subsequently died. The other patient received adjuvant chemotherapy (gemcitabine and capecitabine), and 23 months after the initial operation, no tumor recurrence was detected and the patient is still alive. All other patients remain disease-free. Analysis of 29 fatalities reported in the English literature (including the present case) revealed several atypical features including male gender, old age, tumor size >5 cm, diffuse growth pattern, cellular or nuclear atypia, high mitotic rate, extensive necrosis, extrapancreatic invasion, metastasis and incomplete resection. CONCLUSIONS: SPN is not always indolent. Male patients and those with old age, atypical histopathology (large tumors, diffuse growth, cellular/nuclear atypia, mitotic activity, necrosis, invasion/metastasis) and incomplete resection may have a higher risk of recurrence and death, deserving particular attention.

3 Article High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm. 2018

Aronsson, Linus / Andersson, Roland / Bauden, Monika / Andersson, Bodil / Bygott, Thomas / Ansari, Daniel. ·a Department of Surgery, Clinical Sciences Lund , Skåne University Hospital, Lund University , Lund , Sweden. · b Cambridge Personal Genomics , Cambridge , UK. ·Scand J Gastroenterol · Pubmed #30509115.

ABSTRACT: OBJECTIVE: Glycoproteomics is an emerging subfield of proteomics. Tumor-specific variations in protein glycosylation might be potential targets for the development of new cancer diagnostics. Here, we performed high-throughput screening and targeted verification of glycome alterations in serum samples from patients with pancreatic cancer and the precancerous lesion intraductal papillary mucinous neoplasm (IPMN). MATERIAL AND METHODS: The glycosylation profile of 1000 proteins was mapped in a discovery cohort comprising serum samples from 16 individuals, including 8 patients with pancreatic cancer and 8 healthy controls. The top 10 glycoprotein biomarker candidates with the highest signal intensity difference in glycosylation levels were evaluated in a cohort consisting of 109 serum samples, including 49 patients with resectable pancreatic cancer, 13 patients with resectable noninvasive IPMN and 47 healthy controls, using a targeted assay. RESULTS: Multivariable analysis defined sets of panels comprising CA19-9 and distinctively glycosylated proteins for discrimination between pancreatic cancer, IPMN and healthy controls. A panel including CA 19-9, IL.17E, B7.1 and DR6 gave an AUC of 0.988 at 100% sensitivity at 90% specificity for the discrimination of stage 1 pancreatic cancer and healthy controls. B7.1 was found to be a valuable biomarker for differentiating between IPMN and healthy controls, with better performance alone than CA 19-9. CONCLUSIONS: Measurement of protein glycosylation profiles in serum may aid in the early detection of pancreatic cancer and precursor lesions.

4 Article Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype. 2018

Aronsson, Linus / Ansari, Daniel / Andersson, Bodil / Persson, Ulf / Fridhammar, Adam / Andersson, Roland. ·Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden. · Swedish Institute for Health Economics, IHE, Lund, Sweden. · Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden. Electronic address: roland.andersson@med.lu.se. ·HPB (Oxford) · Pubmed #30064727.

ABSTRACT: BACKGROUND: Branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) presents a clinical conundrum. Rigorous long-term surveillance or surgical resection is recommended. The economic consequences of the management have not been fully investigated. METHODS: A Markov decision model compared 4 strategies for low-risk BD-IPMN: I = upfront total pancreatectomy, II = upfront partial pancreatectomy, III = initial surveillance, IV = watchful waiting. Surveillance was based on the Swedish Guidelines for Pancreatic Cancer. Probabilities and costs were obtained from the participating unit and from the scientific literature. The incremental cost-effectiveness ratios (ICERs) were calculated and sensitivity analyses were performed by varying relevant parameters. Survival was reported in quality-adjusted life-years (QALYs). RESULTS: Strategy III was the most cost-effective strategy with an ICER of €31 682 compared to strategy IV. Strategy I was the most expensive but yielded the best QALY (9.32). Total number of years, annual risk of pancreatic cancer and annual risk of a low-risk BD-IPMN turning into a high-risk lesion had the greatest impact in the model. CONCLUSIONS: Initial surveillance seems to be the most cost-effective strategy in the management of low-risk asymptomatic BD-IPMN. However, the possibility of personalized approaches remains to be investigated.

5 Article Intraductal Papillary Mucinous Neoplasms of The Pancreas: A Nationwide Registry-Based Study. 2018

Aronsson, L / Andersson, B / Andersson, R / Tingstedt, B / Bratlie, S O / Ansari, D. ·1 Departments of Clinical Sciences and Surgery, Lund University and Skane University Hospital, Lund, Sweden. · 2 Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. ·Scand J Surg · Pubmed #29637834.

ABSTRACT: BACKGROUND AND AIMS:: To investigate the paraclinical and pathological features of surgically resected intraductal papillary mucinous neoplasms in Sweden. MATERIALS AND METHODS:: A review of prospectively collected data on patients undergoing pancreatic resection for a histopathologically verified intraductal papillary mucinous neoplasm between 2010 and 2016 was performed using the Swedish National Registry for Pancreatic and Periampullary Cancer. RESULTS:: A total of 3038 pancreatic resections were performed during the study period, of which 251 (8.3%) were due to intraductal papillary mucinous neoplasms. The intraductal papillary mucinous neoplasm cases comprised 227 noninvasive and 24 invasive lesions. There was an annual increase in the number of resected intraductal papillary mucinous neoplasms, from 13 in 2010 to 56 in 2016, and an increase in the proportion of intraductal papillary mucinous neoplasm to the total number of pancreatic resections (4.7%-11%). Biliary obstruction was the only independent predictor of invasive disease, with odds ratio 3.106 (p = 0.030). There was no difference in survival between low-, intermediate-, and high-grade dysplastic lesions (p = 0.417). However, once invasive, the prognosis was severely impacted (p < 0.001). Three-year survival was 90% for noninvasive intraductal papillary mucinous neoplasm and 39% for invasive intraductal papillary mucinous neoplasm. Survival was better in lymph node negative invasive intraductal papillary mucinous neoplasm (p = 0.021), but still dismal compared to noninvasive lesions (p < 0.001). CONCLUSION:: The number of surgically resected intraductal papillary mucinous neoplasms is increasing in Sweden. Biliary obstruction is associated with invasive disease. Low-to-high-grade dysplastic intraductal papillary mucinous neoplasm has an excellent prognosis, while invasive intraductal papillary mucinous neoplasm has a poor survival rate.

6 Article Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. 2017

Bauden, Monika / Kristl, Theresa / Sasor, Agata / Andersson, Bodil / Marko-Varga, György / Andersson, Roland / Ansari, Daniel. ·Department of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital, SE-221 85, Lund, Sweden. · Clinical Protein Science & Imaging, Department of Biomedical Engineering, Lund University, Biomedical Center, Lund, Sweden. · Department of Pathology, Skåne University Hospital, Lund, Sweden. · Department of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital, SE-221 85, Lund, Sweden. daniel.ansari@med.lu.se. ·BMC Cancer · Pubmed #29197353.

ABSTRACT: BACKGROUND: Epigenetic alterations have been recognized as important contributors to the pathogenesis of PDAC. However, the role of histone variants in pancreatic tumor progression is still not completely understood. The aim of this study was to explore the expression and prognostic significance of histone protein variants in PDAC patients. METHODS: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed for qualitative analysis of histone variants and histone related post-translational modifications (PTMs) in PDAC and normal pancreatic tissues. Survival analysis was conducted using the Kaplan-Meier method and Cox proportional hazards regression. RESULTS: Histone variant H1.3 was found to be differentially expressed (p = 0.005) and was selected as a PDAC specific histone variant candidate. The prognostic role of H1.3 was evaluated in an external cohort of patients with resected PDAC using immunohistochemistry. Intratumor expression of H1.3 was found to be an important risk factor for overall survival in PDAC, with an adjusted HR value of 2.6 (95% CI 1.1-6.1), p = 0.029. CONCLUSION: We suggest that the intratumor histone H1.3 expression as reported herein, may serve as a new epigenetic biomarker for PDAC.

7 Article Development and 2017

Urey, Carlos / Hilmersson, Katarzyma Said / Andersson, Bodil / Ansari, Daniel / Andersson, Roland. ·Department of Surgery, Clinical Sciences Lund, Skane University Hospital, Lund University, Lund, Sweden. · Department of Surgery, Clinical Sciences Lund, Skane University Hospital, Lund University, Lund, Sweden roland.andersson@med.lu.se. ·Anticancer Res · Pubmed #29061782.

ABSTRACT: BACKGROUND/AIM: Pancreatic Ductal adeno-carcinoma (PDAC) is a devastating disease. Gemcitabine is the standard chemotherapeutic agent against PDAC but has only limited effectiveness. The aim of the study was to develop and study the targeting affinity and in vitro antiproliferative effect of a MUC4-targeted gemcitabine-loaded immuno-liposome for treatment of PDAC. MATERIALS AND METHODS: Gemcitabine-loaded immunoliposomes were developed by grafting anti-MUC4 antibodies to the liposomal surface. Targeting affinity was compared in vitro between immunoliposomes and non-targeted liposomes and anti-proliferative effect was compared in vitro between free drug, non-targeted liposomal gemcitabine and MUC4-targeted immunoliposomal gemcitabine on a MUC4-positive pancreatic cancer cell line, Capan-1. RESULTS: Development of a MUC4-targeted immunoliposome was confirmed and characterized by immunoblots and size characterization. The MUC4-targeted immunoliposome showed a significantly higher targeting affinity compared to the non-targeted liposomes and also showed an improved antiproliferative effect compared to free and non-targeted liposomal drug. CONCLUSION: Successful development and characterization of a MUC4-targeted immunoliposome shows promising results for a targeted treatment and improved retention of gemcitabine for treatment of PDAC.

8 Article Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. 2017

Urey, Carlos / Andersson, Bodil / Ansari, Daniel / Sasor, Agata / Said-Hilmersson, Katarzyna / Nilsson, Johan / Andersson, Roland. ·a Department of Surgery , Clinical Sciences Lund, Skåne University Hospital, Lund University , Lund , Sweden. · b Department of Pathology , Skåne University Hospital, Lund University , Lund , Sweden. · c Department of Cardiothoracic Surgery, Clinical Sciences Lund , Skåne University Hospital, Lund University , Lund , Sweden. ·Scand J Gastroenterol · Pubmed #28270046.

ABSTRACT: BACKGROUND: Previous in vitro studies have shown that mucin 4 (MUC4) confers resistance toward gemcitabine in pancreatic cancer cells. To date, there are few clinical studies corroborating these findings. The aim of this study was to evaluate the predictive impact of MUC4 expression on survival in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. MATERIALS AND METHODS: MUC4 expression was investigated by immunohistochemistry in 78 tissue sections from patients with pancreatic ductal adenocarcinoma undergoing Whipple resection. The H-score was used to evaluate MUC4 expression. The Kaplan-Meier method and Cox proportional hazards regression analysis were used to assess the predictive role of MUC4 expression. RESULTS: The MUC4 protein was expressed in 93.6% (73/78) of pancreatic cancer tissue specimens. None of the normal control pancreatic tissues had any MUC4 expression. Low MUC4 expression (H-score ≤100) was detectable in 42 (53.8%) of tumors and high MUC4 expression (H-score >100) was detectable in 36 (46.2%) of tumors. Low expression of MUC4 was associated with favorable survival (p = .027), whereas high MUC4 expression did not correlate with survival (p = .87) in patients receiving adjuvant gemcitabine treatment. CONCLUSIONS: This is the first study indicating a predictive role of MUC4 expression for gemcitabine treatment in the clinical setting.

9 Article Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. 2015

Bauden, Monika / Pamart, Dorian / Ansari, Daniel / Herzog, Marielle / Eccleston, Mark / Micallef, Jake / Andersson, Bodil / Andersson, Roland. ·Department of Surgery, Clinical Sciences, Lund, Lund University and Skåne University Hospital, Lund, SE-221 85 Lund, Sweden. · Belgian Volition SA-Centre Technologique, Rue du Séminaire, 20A BE-5000 Namur Belgium. ·Clin Epigenetics · Pubmed #26451166.

ABSTRACT: BACKGROUND: To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method. RESULTS: Multivariate analysis defined a panel of five serum cfnucleosome biomarkers that gave an area under the curve (AUC) of 0.95 for the discrimination of pancreatic cancer from healthy controls, which was superior to the diagnostic performance of the common pancreatic tumor biomarker, carbohydrate antigen 19-9 (CA 19-9) with an AUC of 0.87. Combining CA 19-9 with a panel of four cfnucleosome biomarkers gave an AUC of 0.98 with an overall sensitivity of 92 % at 90 % specificity. CONCLUSIONS: The present study suggests that global epigenetic profiling of cfnucleosomes in serum using a simple NuQ(®) immunoassay-based approach can provide novel diagnostic biomarkers in pancreatic cancer.

10 Article Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. 2015

Ansari, Daniel / Andersson, Roland / Bauden, Monika P / Andersson, Bodil / Connolly, Joanne B / Welinder, Charlotte / Sasor, Agata / Marko-Varga, György. ·Department of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital, 221 85, Lund, Sweden. ·J Cancer Res Clin Oncol · Pubmed #25216700.

ABSTRACT: PURPOSE: Pancreatic cancer is commonly detected at advanced stages when the tumor is no longer amenable to surgical resection. Therefore, finding biomarkers for early stage disease is urgent. Here, we show that high-definition mass spectrometry (HDMS(E)) can be used to identify serum protein alterations associated with early stage pancreatic cancer. METHODS: We analyzed serum samples from patients with resectable pancreatic cancer, benign pancreatic disease, and healthy controls. The SYNAPT G2-Si platform was used in a data-independent manner coupled with ion mobility. The dilution of the samples with yeast alcohol dehydrogenase tryptic digest of known concentration allowed the estimated amounts of each identified protein to be calculated (Silva et al. in Anal Chem 77:2187-2200, 2005; Silva et al. in Mol Cell Proteomics 5:144-156, 2006). A global protein expression comparison of the three study groups was made using label-free quantification and bioinformatic analyses. RESULTS: Two-way unsupervised hierarchical clustering revealed 134 proteins that successfully classified pancreatic cancer patients from the controls, and identified 40 proteins that showed a significant up-regulation in the pancreatic cancer group. This discrimination reliability was further confirmed by principal component analysis. The differentially expressed candidates were aligned with protein network analyses and linked to biological pathways related to pancreatic tumorigenesis. Pancreatic disease link associations could be made for BAZ2A, CDK13, DAPK1, DST, EXOSC3, INHBE, KAT2B, KIF20B, SMC1B, and SPAG5, by pathway network linkages to p53, the most frequently altered tumor suppressor in pancreatic cancer. CONCLUSION: These pancreatic cancer study candidates may provide new avenues of research for a noninvasive blood-based diagnosis for pancreatic tumor stratification.

11 Article Artificial neural networks predict survival from pancreatic cancer after radical surgery. 2013

Ansari, Daniel / Nilsson, Johan / Andersson, Roland / Regnér, Sara / Tingstedt, Bobby / Andersson, Bodil. ·Department of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden. ·Am J Surg · Pubmed #23245432.

ABSTRACT: BACKGROUND: Artificial neural networks (ANNs) are nonlinear pattern recognition techniques that can be used as a tool in medical decision making. The objective of this study was to develop an ANN model for predicting survival in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: A flexible nonlinear survival model based on ANNs was designed by using clinical and histopathological data from 84 patients who underwent resection for PDAC. RESULTS: Seven of 33 potential risk variables were selected to construct the ANN, including lymph node metastasis, differentiation, body mass index, age, resection margin status, peritumoral inflammation, and American Society of Anesthesiologists grade. Three variables (ie, lymph node metastasis, leukocyte count, and tumor location) were significant according to Cox regression analysis. Harrell's concordance index for the ANN model was .79, and for Cox regression it was .67. CONCLUSIONS: For the first time, ANNs have been used to successfully predict individual long-term survival for patients after radical surgery for PDAC.